Trial
NCT02485990
Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
AstraZeneca; MedImmune LLC
Condition
Primary Peritoneal Carcinoma
Intervention
Tremelimumab
Why stopped
Withdrawal of sponsor support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-12